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Mycobacterium tuberculosis is a highly infectious pathogen that is still responsible for millions
of deaths annually. Effectively treating this disease typically requires a course of antibiotics,
most of which were developed decades ago. These drugs are, however, not effective against
persistent tubercle bacilli and the emergence of drug-resistant stains threatens to make many
of them obsolete. The identiﬁcation of new drug targets, allowing the development of new
potential drugs, is therefore imperative. Both proteomics and structural biology have
important roles to play in this process, the former as a means of identifying promising drug
targets and the latter allowing understanding of protein function and protein–drug interac-
tions at atomic resolution. The determination of M. tuberculosis protein structures has been a
goal of the scientiﬁc community for the last decade, who have aimed to supply a large amount
of structural data that can be used in structure-based approaches for drug discovery and
design. Only since the genome sequence of M. tuberculosis has been available has the
determination of large numbers of tuberculosis protein structures been possible. Currently,
the molecular structures of 8.5% of all the pathogen’s protein-encoding ORFs have been
determined. In this review, we look at the progress made in determining the M. tuberculosis
structural proteome and the impact this has had on the development of potential new drugs,
as well as the discovery of the function of crucial mycobaterial proteins.
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1 Introduction
Tuberculosis (TB) is an ancient human disease. Evidence of
infection with Mycobacterium tuberculosis, the causative
agent of TB, has been dated to the Neolithic period (7000
BC) and has been observed in Egyptian mummies
(2050–500 BC) [1, 2]. Reference is made to TB in literature
from both ancient China and India dating to 4000–2000 BC
as well as in biblical scripture [3]. Historically known as
consumption in the West, TB was a common disease that
led to the death of many historic ﬁgures (e.g. John Keats,
D. H. Lawrence, George Orwell, Immanuel Kant, Florence
Nightingale etc.) and so has particularly inﬂuenced
European history, and became a theme in art, literature and
ﬁlm. Only in the last century has effective chemotherapeutic
treatment been developed against TB. Several antibiotics
were discovered in the 1940s and 1950s that led to an initial
decline of TB, particularly in developed countries. In the last
few decades, however, TB has been resurgent. Driven by
poverty, overcrowding and the spread of the human
immunodeﬁciency virus (HIV) in the developing world, TB
has been responsible for the death of 30 million people
worldwide in the last decade [3]. A third of the world’s
population is thought to be infected and 10% of these carry a
lifetime risk of developing the disease [3]. These worrying
facts led the World Health Organization (WHO) to declare
TB a global health emergency in 1993 [4].
M. tuberculosis is highly infectious and is highly adapted
to surviving in the host by being able to evade clearance by
the immune system and remaining inactive but viable for
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million new cases of TB were recorded in 2009 of which 1.7
million were fatal (World Health Organization, Global
tuberculosis control 2010, http://www.who.int/tb/publica-
tions/global_report/2010/en/index.html). While prevalence
of the disease has declined in the industrialized countries,
the disease burden in developing countries remains high.
TB is the second major cause of death from an infectious
pathogen after HIV [3]. In the past century, great strides
have been made in treating the disease. There are effective,
but complex and often costly, multi-drug treatment regimes
that can cure the disease in several months and prevent
those who have been in contact with patients from devel-
oping the disease. Even in resource-poor settings the treat-
ment strategy DOTS (Directly Observed Therapy, Short
Course), which aims to ensure effective therapy, has proven
successful in treating TB where properly implemented [3].
Where the treatment has been ineffectively implemented,
drug-resistant strains of M. tuberculosis have arisen that pose
a renewed threat to global health. Both multi-drug resistant
and extensively drug-resistant M. tuberculosis strains have
arisen, which are resistant to many of the front-line drugs
currently in use [3]. There is therefore a clear need for the
development of new drugs and the identiﬁcation of new
drug targets. Proteomics and structural biology have a clear
role to play in this endeavour. In recent years, several papers
have reported the identiﬁcation of potentially interesting
new protein drug targets [5, 6]. Understanding the function
of these proteins, and indeed also that of existing protein
drug targets, often requires detailed knowledge of their
structure. In this review, we document the progress that has
been made in characterizing the M. tuberculosis structural
proteome.
2 The structural proteome of M.
tuberculosis in numbers
Structural genomics initiatives are responsible for approxi-
mately 25% of the determined TB protein structures (Fig. 1).
These initiatives, together with the efforts of conventional
structural biology groups, have had an enormous impact on
the understanding of M. tuberculosis biology. The available
structural data have already led to the identiﬁcation of
several potential new drug targets (reviewed in [6–8]) and
has been helpful in assigning functions to what were
previously proteins of unknown function [9, 10].
One of the biggest breakthroughs in TB research has
been the sequencing of the M. tuberculosis genome (speci-
ﬁcally that of the laboratory strain H37Rv), which was
completed in 1998 and re-annotated in 2002 [11, 12]. The
genome sequence offered a great opportunity to understand
mycobacterial pathogenesis. Genes important for growth,
virulence and persistence are beginning to be identiﬁed.
Approximately 20% of the structures of proteins involved in
virulence and detoxiﬁcation have been determined and
represent the largest proportion of structures solved of any
functional class (see below). The sequencing of the genome
led to a marked overall increase in the number of structures
of M. tuberculosis proteins deposited in the Protein Data
Bank (PDB) (Fig. 2). The ﬁrst TB protein structure was
determined in 1994 [13]. In the following 6 years only ten
more structures were reported. After the genome sequence
of M. tuberculosis became publicly available, the number of
structures determined after 2000 increased dramatically and
at an increasing rate. Initial structural genomics efforts
found protein solubility to be a major bottleneck in structure
determination [14]. Subsequently, methods have been
developed that remedied this early problem, such as the
development of customized expression strategies for TB
proteins in Escherichia coli [15] or the use of Mycobacterium
smegmatis as a heterologous expression strain, as well as the
co-expression of proteins using their native-operon structure
[16]. The increase in determined structures is also no doubt
due in part to the development of improved methods for
high-throughput crystallography. However, the key event
that led to this increase was the availability of genome-wide
sequence data as of 1998.
There are currently 69351 structures in the PDB of
which 1.3%, a total of 898, are structures of M. tuberculosis
proteins. Of these proteins 327 are distinct, which repre-
sents 8.5% of the approximately 4000 polypeptide-encoding
ORFs in the M. tuberculosis genome (Table 1; [12]). A
complete list of M. tuberculosis protein structures deposited
in the PDB is given in the Supporting Information Table S1.
The predominant method used to determine these struc-
Figure 1. Analysis of M. tuberculosis protein
structures deposited in the PDB. Shown is
the proportion, in percentage of the total
number of currently deposited structures
(898), that were determined by X-ray crys-
tallography or NMR, the proportion of struc-
tures that are ligand-bound, the proportion of
structures determined by structural geno-
mics initiatives and the proportion of crystal
structures (873) in the different given reso-
lution ranges.
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the total number of TB structures currently determined
(Fig. 1). A further 25 were elucidated by NMR spectroscopy.
Most structures are of individual proteins, although many
are bound by small molecule ligands such as enzymatic
substrates, products, substrate analogues, cofactors and
lipids (Fig. 1). Only 11 protein–nucleic acid complexes have
been determined and there are very few structures of
protein–protein complexes (o10) and none of TB–host
protein complexes.
M. tuberculosis proteins have been broadly classiﬁed into
ten categories according to their function [12]. Table 1 lists
these categories and the number of ORFs and structures in
each. Classes 4 and 5 are RNA-encoding genes and inser-
tions or phage sequences, respectively. These two classes are
not considered in this review. We have restricted ourselves
to an analysis of M. tuberculosis protein-encoding genes. By
far, the largest number of structures to be determined to
date is those of enzymes that are responsible for inter-
mediate metabolism and respiration (class 7). This class also
contains the largest number of ORFs in the M. tuberculosis
genome. About 16% of all the ORFs in this category have a
representative structure. An equal proportion of structures
are available for class 6, the regulatory proteins, and slightly
more, approximately 20%, for class 0, the virulence, detox-
iﬁcation and adaptation category. Structures of lipid meta-
bolising proteins, class 1, and those that encode information
processing proteins, class 2, are somewhat less well repre-
sented in the PDB, but each still cover more then one-tenth
of the ORFs in these categories. The categories in which the
M. tuberculosis structural proteome is under-represented,
given the number of ORFs and the progress made in other
categories, are the cell wall and cell processes associated
proteins (class 3), the proline-glutamate (PE) and proline-
proline-glutamate (PPE) proteins (class 6) and the conserved
hypothetical proteins (class 10). Only 4.4% of the cell wall
and cell processes encoding ORFs have a representative
structure, whereas only 4.1% of the conserved hypothetical
proteins have a determined structure. The PE and PPE
proteins, a family of proteins that are encoded by about 5%
of the M. tuberculosis genome, have no clearly deﬁned
function and only two representative structures have been
reported for this class. That represents a mere 1.2% of these
genes. It therefore seems, given that structural data has
proven useful for the discovery of protein function (see
Figure 2. The number of M. tuberculosis structures deposited in
the PDB to date (December 2010). The ﬁrst structure was deter-
mined in 1994. In 2000 a total of 11 structures had been deter-
mined, by 2005 a total of 203 and by 2010 almost 900 structures
had been deposited in the PDB. The ﬁrst publication of the
M. tuberculosis H37Rv genome sequence is indicated. The
structures are those of proteins that are targeted by front-line
anti-TB drugs and the proteasome. The year of their deposition
in the PDB is indicated with arrows on the time-line. The
isoniazide and ethionamide target is inhA (1ENY) [34]. Isoniazide
is a pro-drug and needs to be activated by KatG (1SJ2) [35]. The
ﬂuoroquinolones target gyrA (3ILW) and pyrazinamide pncA
(3GBC). Rifampin and streptomycin target the ribosome, of
which no TB structure has been determined.
Table 1. Functional classiﬁcation of M. tuberculosis proteins and the available structural data for each class
Class
a) Function ORFs
a) Structures %Structures/ORFs Folds
b) Structures/fold
0 Virulence, detoxiﬁcation, adaptation 99 20 20.2 15 1.3
1 Lipid metabolism 233 31 13.3 9 3.4
2 Information pathways 229 25 10.9 9 2.8
3 Cell-wall and cell processes 708 31 4.4 11 2.8
6 PE and PPE proteins 170 2 1.2 1 2
7 Intermediate metabolism and respiration 894 143 16.0 35 4.1
8 Proteins of unknown function 272 0 – – –
9 Regulatory proteins 189 32 16.9 11 2.9
10 Conserved hypothetical proteins 1051 43 4.1 15 2.9
Total protein encoding ORFs 3845 327 8.5
a) Deﬁnition of classes and the number of protein-encoding ORFs in the M. tuberculosis are as given in Camus et al. [12]. Class 4 are RNA-
encoding genes and class 5 are insertion sequences and phages and were not included in this analysis.
b) The number of different folds in each functional class are based on the SCOP (http://scop.mrc-lmb.cam.ac.uk/scop/) annotation of the
structures given in the Supporting Information Table S1. Only those structures, in total 112, that are annotated in SCOP were
considered, which represents 34% of all the distinct protein structures.
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the structures of this poorly understood protein family.
3 Structure-based discovery of protein
function
Over one-quarter of the M. tuberculosis genome encodes
conserved hypothetical proteins and 43 of their structures
have been determined (Table 1). It is well established that
structural motifs and topology are more conserved over
evolutionary time than are protein sequences [17]. The
determination of the structures of these hypothetical
proteins may therefore supply some clues as to their biolo-
gical function. There are several recent examples of the
successful use of structural knowledge to predict function.
The function of the enzyme deazaﬂavin-dependent
nitroreductase (Ddn), previously only known as the hypo-
thetical protein Rv3547, was discovered using its homology
to Rv1155 and Rv2991 [18, 19]. The structures of these two
proteins were determined by the TB Structural Genomics
Consortium and have structural homology to ﬂavin mono-
nucleotide-binding proteins and Nim-proteins that confer
resistance to 5-nitroimidazole antibiotics in Bacteroides
species. Rv3547 is a protein of 151 amino acid residues that
had no detectable sequence homology to any other protein
of known function [18]. Based on its similarity to the two
structures, Manjunatha et al. proposed that Rv3547 is a
previously uncharacterised class of nitroreductase [18].
Subsequently, the enzymatic activity of Rv3547 has been
veriﬁed [19].
In a similar case, the structure of Rv2175c, originally
annotated as a protein of unknown function, revealed that it
possesses an original winged helix-turn-helix motif indica-
tive of a DNA-binding activity [20]. DNA-binding of Rv2175c
was conﬁrmed by ﬂuorescence anisotropy and in electro-
phoretic mobility shift assays [20]. Furthermore, the protein
is a substrate of PknL kinase, which negatively regulates
Rv2175c’s DNA-binding activity by phosphorylating its
N-terminus. Its structure, determined by multidimensional
NMR, revealed that the N-terminus of the protein is natively
unfolded. This N-terminal region seems to be restricted to
the species of the M. tuberculosis complex, which prompted
Cohen-Gonsaud et al. to suggest that this may be a regula-
tory system unique to these bacteria [20].
M. tuberculosis adapts to stress conditions such as a
decrease in oxygen by upregulating the dormancy survival
regulon, which is associated with the bacterium’s ability to
enter a nonreplicating persistent state in the host [21]. One
of the most strongly upregulated ORFs of this regulon is
Rv2626c, which encodes a protein called hypoxic response
protein 1. Its structure reveals the presence of two disul-
phide bonds, a structural feature unusual in intracellular
proteins, which led to the suggestion that it might be
secreted in vivo [22]. Tantalizingly, immunogold electron
microscopy localization of hypoxic response protein 1
showed it to be extracellular and, most recently, the protein
was indeed shown to modulate macrophage effector func-
tions [22, 23]. No known signal sequence could be found
encoded in Rv2626c. The gene sequence was therefore not
predictive of an extracellular function while the structure
was. As the above examples and many more reviewed else-
where [9, 10] demonstrate, structural data can be extremely
valuable in assigning function to hypothetical proteins. No
doubt the continuing efforts to determine structures of
M. tuberculosis proteins will lead to greater understanding of
this pathogen’s biology.
4 Structure-based drug discovery
Structural biology can provide molecular details of interac-
tions that are invaluable in understanding the relationships
between protein structure and ligand activity, especially
when these are drugs or potential drug lead compounds.
There are several successful examples of marketable drugs
that were developed using protein structure information: the
HIV protease inhibitors Viracept [24], Agenerase [25] and
Aluviran [26] are such examples. Despite these successes,
not many drugs have been developed in this manner. There
is, however, growing activity in this area within the TB
research community [6]. The ongoing efforts to determine
large numbers of TB structures are based on the expectation
that these are an important source of information for drug
discovery programs. Given the dramatically increased
wealth of structural data on TB proteins in the last 10 years
(Fig. 2), structure-based drug design initiatives have gained
momentum, but have as yet to lead to a marketable drug.
Most TB protein structures, a total of 688, are of high
resolution having been determined with diffraction data
better than or equal to 2.5A ˚ and of these, 350 have resolu-
tions better than 2.0A ˚ (Fig. 1). Since the ability to determine
the structure of a protein–ligand complex at high resolution
is an absolute requirement for structure-based drug design,
a large number of TB protein structures would therefore be
amenable to such methods. Additional information about
M. tuberculosis structural genomics data from the US is
available over the following link: http://www.webtb.org/.
Even though there has been no drug developed against
TB as yet using structure-based methods, one recent
example of drug-lead development targeting an E. coli
protein conserved in mycobacteria can serve as an example.
A class of amino-oxazoles with antibacterial activity has been
identiﬁed by researchers of the pharmaceutical company
Pﬁzer as potential drug leads [27, 28]. Initially, a class of
pyridopyrimidines were identiﬁed as selective inhibitors of
the E. coli biotin carboxylase, the protein that catalyses the
ﬁrst committed step in lipid metabolism [27]. These weak-
binding small-molecule ligands were then used as building
blocks for inhibitors, which through iterative cycles of
structure-based drug design that included virtual screening
and fragment-based approaches improved the potency of the
Proteomics 2011, 11, 3128–3133 3131
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physicochemical properties were maintained and resulted in
competitive inhibitors that target the biotin carboxylase
ATP-binding site.
Screening for inhibitors of TB proteins has been
performed on several target proteins and in some cases the
structure of the proteins are known. This may allow for
structure-based drug design of TB speciﬁc inhibitors. One
set of such potential drug leads has been reported for the
carboxyltransferase domain of the M. tuberculosis acetyl-CoA
carboxylase [29]. So far, several computational analyses have
led to the prediction of potential drug leads, a process that
also relies on the availability of structural data, but this has
not yet been followed by actual empirical data. The full
potential of structural data to aid the discovery and design of
new anti-TB drugs therefore remains to be realized.
However, there are some encouraging examples of this. For
instance, analysis of the crystal structures of M. tuberculosis
InhA, the target of the front-line anti-TB drug isoniazide,
has been used in structure-based design of potential new
drugs [30]. Also, structure-based design of DevR inhibitors
against nonreplicating M. tuberculosis has recently been
reported [31].
5 Synergy between proteomics and
structural genomics
Some recent publications on proteomics and structural
biology may represent a new trend in the search for new
drug targets [32, 33]. Recent proteomics experiments, such
as the use of a guinea pig model of aerosol infection to study
the M. tuberculosis proteome in vivo, have given insight into
the expression proﬁle of many of the pathogen’s genes [33].
Over 500 proteins were identiﬁed over the course of infec-
tion with several classes such as class 3, cell wall and cell
processes, and class 7, intermediate metabolism and
respiration, accounting for almost half of these. These
indicate new potential targets for structural biology and drug
development. More recently, the combination of structural
data, modelling and knowledge of drug interactions with
proteins was used to determine the drugome of M. tuber-
culosis [32]. This study made use of all the structures of TB
proteins currently in the PDB and modelled several hundred
more to cover approximately 43% of the M. tuberculosis
proteome. Existing data on protein–drug interactions were
used to determine the theoretical proteome-wide drug
interaction network, which identiﬁed multiple proteins that
may already be targeted by existing drugs and that may serve
as useful templates for new drugs.
6 Concluding remarks
Currently, the molecular structures of 8.5% of the ORF of
M. tuberculosis have been determined. This has been one of
the major achievements within the TB research community
during the last decade. The availability of structural data has
been invaluable in advancing our understanding of the
biology of M. tuberculosis. Protein functions could be
assigned or re-assigned to many proteins and structural data
are being used ever more frequently in the rational design
and discovery of new anti-TB drugs. There is continued
interest in determining more TB structures and comple-
mentation of structural biology with proteomics promises to
be a productive new area of research.
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